Semaglutide clinical uses
Pro Research Analysisby 
Searched over 200M research papers
Semaglutide Clinical Uses in Type 2 Diabetes
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for the treatment of type 2 diabetes mellitus (T2DM). It is available in both once-weekly subcutaneous injection and once-daily oral formulations. Semaglutide is used as monotherapy or as an add-on to other glucose-lowering agents, including insulin, when diet and exercise alone do not provide adequate glycemic control. Clinical trials and real-world studies have shown that semaglutide effectively lowers blood sugar (HbA1c), reduces body weight, and has a low risk of hypoglycemia. It is suitable for a wide range of patients, including those with hepatic or renal impairment, and is recommended in international diabetes treatment guidelines Andersen2021Gallwitz2021Hall2018+2 MORE.
Semaglutide for Obesity and Weight Management
Semaglutide is also approved for the treatment of overweight and obesity. Clinical trials, such as the STEP program, have demonstrated significant weight loss in people with overweight or obesity, with or without T2DM. Patients treated with semaglutide achieved average weight losses of 10–17% over 68–104 weeks, and a high proportion reached clinically meaningful weight loss targets. These results have been confirmed in both clinical trials and real-world settings, supporting semaglutide’s use as an effective weight management therapy Mahapatra2022Bergmann2022Ghusn2022.
Cardiovascular and Metabolic Benefits
Semaglutide has shown benefits beyond glycemic control and weight loss. It has demonstrated reductions in major adverse cardiovascular events and improvements in cardiometabolic risk factors, such as blood pressure and lipid profiles. Its cardiovascular safety profile is considered non-inferior to placebo, making it a favorable option for patients at risk of cardiovascular disease Andersen2021Gallwitz2021Bergmann2022+1 MORE.
Potential Uses in Other Conditions
Emerging evidence suggests that semaglutide may have therapeutic potential in other conditions. Studies indicate possible benefits in non-alcoholic steatohepatitis (NASH) and neurodegenerative diseases like Parkinson’s and Alzheimer’s, due to its effects on insulin resistance and neuroprotection. Additionally, preclinical research supports further investigation of semaglutide for alcohol use disorder, as it has been shown to reduce alcohol intake in animal models Mahapatra2022Chuong2023.
Safety and Tolerability
Semaglutide is generally well-tolerated. The most common side effects are gastrointestinal, such as nausea and diarrhea, which are usually mild and transient. The risk of hypoglycemia is low, and no significant increase in cardiovascular or other serious adverse events has been observed compared to placebo or other treatments. Its safety profile supports its use in a broad range of patients with T2DM and obesity Andersen2021Gallwitz2021Bergmann2022+3 MORE.
Conclusion
Semaglutide is a versatile medication with established clinical uses in type 2 diabetes and obesity, offering effective glycemic control, significant weight loss, and cardiovascular benefits. Its favorable safety profile and potential for broader therapeutic applications make it an important option in modern clinical practice. Ongoing research may expand its indications to additional metabolic and neurodegenerative diseases.
Sources and full results
Most relevant research papers on this topic